CDC Update: Total Depletion of Yellow Fever Vaccine in US

Share this content:
Stamaril® will be made available at a limited number of clinics throughout the United States and certain territories.
Stamaril® will be made available at a limited number of clinics throughout the United States and certain territories.

Sanofi Pasteur has announced the total depletion of their stock of yellow fever vaccine (YF-VAX) as of July 24, 2017.

YF-VAX, the only yellow fever vaccine licensed in the United States, will be unavailable for ordering until mid-2018 according to an article published in the Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report.

In preparation for stock depletion until their new manufacturing facility is completed, Sanofi Pasteur submitted an investigational new drug application in 2016 to the US Food and Drug Administration (FDA) to allow importation and use of Stamaril®. Stamaril, which is licensed and distributed in approximately 70 countries, has similar safety and efficacy to YF-VAX. The FDA accepted Sanofi Pasteur's application in October 2016.

While YF-VAX may be available at some clinics until supplies are exhausted, Stamaril will be made available at a limited number of clinics throughout the United States and certain territories.

More information regarding the limited access of YF-VAX can be found on Sanofi Pasteur's website. Locations of clinics offering Stamaril vaccine and clinics with remaining doses of YF-VAX can be found on the CDC's website


Reference

Gershman MD, Sotir MJ. Update: temporary total depletion of US licensed Yellow Fever vaccine for civilian travelers addressed by investigational new drug use of imported Stamaril vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:780.

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters